CCRM News

1. MicrofluidX And CCRM Partner On End-To-End Bioprocessing Of CAR-T Cell Therapies 1/11/2023

   MicrofluidX (MFX), a UK-based provider of next-generation bioreactors for cell research and manufacturing, announced a partnership with CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies, to advance manufacturing of lentivirus (LV) CAR-T cells with their next generation platform, the Cyto Engine™.

2. Funding From Ontario Government Launches OmniaBio Inc. 3/31/2022

   OmniaBio Inc., a subsidiary of CCRM, is the first project to be funded under the Invest Ontario Fund. OmniaBio Inc’s new facility will be the largest CDMO in Canada for the manufacture of CGTs.

3. CCRM Launches Venture Investment Arm: CCRM Enterprises 12/23/2021

   CCRM, a leader in developing and commercializing regenerative medicine technologies and cell and gene therapies, has launched CCRM Enterprises Inc. to distinguish its not-for-profit operations from its for-profit commercial and investment endeavours. This new entity will invest in promising startups, early-stage regenerative medicine-based technologies, and cell and gene therapy companies.

4. CCRM Enterprises Invests In Mediphage’s Novel Gene Therapy Platform 12/16/2021

   The investment from CCRM Enterprises will be used to fund the development of the technology and ongoing operations, and includes access to CCRM’s scientific and manufacturing expertise.

5. Exacis Biotherapeutics Announces Strategic Partnership With CCRM For Specialty Manufacturing Of Services And Investment For Development Of iPSC-Derived mRNA-Engineered NK Cells 10/26/2021

   Exacis CEO Gregory Fiore, MD, commented, “We welcome CCRM as a key partner to allow us to rapidly advance our virus-free manufacturing processes to make novel NK cell products that are engineered for performance and to avoid rejection. CCRM is a recognized leader in iPSC-derived cell therapy development and manufacturing and we are thrilled to have them as a partner."

6. CellCAN And CCRM Partner To Launch CATTI 7/29/2021

   CellCAN, a knowledge mobilization network in cell and gene therapies (CGTs), and CCRM, a leader in developing and commercializing regenerative medicine-based technologies and CGTs, are responding to that challenge by launching the Canadian Advanced Therapies Training Institute (CATTI).

7. CCRM Turns 10: What Does This Mean For Cell And Gene Therapy In Canada? 6/14/2021

   CCRM’s 10-year anniversary provides an opportunity to reflect on its accomplishments and how it has helped catalyze an industry in Canada. In the next decade, Canadians can expect to see growth in the manufacturing and delivery of cell and gene therapies for Canadians and people around the world.

8. CCRM Signs Agreements With Canadian And International Institutions To Advance Regenerative Medicine Inventions 6/1/2021

   CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies, stands ready to help chart optimal commercialization pathways and translate research findings into new companies. To that end, CCRM has developed and signed alliance agreements in Canada and abroad to support promising discoveries wherever they originate.

9. CCRM And Amgen Partner To Advance Emerging Medical Innovations 4/29/2021

   CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies, and Amgen, a global leader in the biotechnology industry, are announcing a multi-year fund, for early-stage regenerative medicine-based technologies and therapies to benefit patients and the health-care system.

10. CCRM And Mcmaster Innovation Park (MIP) Partner To Build And Operate Biomanufacturing Campus 11/12/2020

    CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies, and McMaster Innovation Park (MIP), Canada's Premier Innovation Park, announce they have signed a Letter of Intent (LOI) to partner in the development of a biomanufacturing campus at MIP focused on regenerative medicine-based technologies and cell and gene therapies.